What is Bioniq?
Founded in 2019 and headquartered in London, Bioniq occupies a critical intersection between biotechnology and consumer wellness. By utilizing sophisticated artificial intelligence to interpret complex blood test data, the company provides a data-backed alternative to the traditional, one-size-fits-all supplement market. This precision-health approach has positioned Bioniq as an industry leader, effectively bridging the gap between clinical diagnostics and daily nutritional optimization. The firm's scalable platform is designed to meet the growing demand for personalized health solutions, catering to high-performance individuals and health-conscious consumers alike.
How much funding has Bioniq raised?
Bioniq has raised a total of $22.8M across 2 funding rounds:
Series A
$7.8M
Series B
$15M
Series A (2021): $7.8M with participation from OKS Group incorporated
Series B (2024): $15M led by HV Capital and Unbound
Key Investors in Bioniq
HV Capital
HV Capital is a prominent European venture firm that focuses on early-stage and growth-stage investments, providing significant support to companies scaling their digital business models.
Unbound
Unbound is a strategic investment firm known for backing high-growth technology companies that demonstrate significant potential for market disruption.
OKS Group incorporated
OKS Group is a diversified investment entity that provides capital and operational support to businesses seeking to optimize their service delivery and technological frameworks.
What's next for Bioniq?
With the successful closure of its latest financing round, Bioniq is well-positioned to scale its operations and enhance its technological infrastructure. The company is expected to focus on deepening its AI capabilities, expanding its market reach, and potentially integrating further diagnostic tools into its ecosystem. As the personalized nutrition market continues to mature, Bioniq's ability to maintain its data-driven competitive advantage will be paramount. The strategic backing received will likely facilitate broader international market penetration and the refinement of its supply chain, ensuring that the company remains at the forefront of the health-tech innovation curve.
See full Bioniq company page
